Zhao Fang-Hui, Hu Shang-Ying, Wang Shao-Ming, Chen Feng, Zhang Xun, Zhang Wen-Hua, Pan Qin-Jing, Qiao You-Lin
Cancer Institute and Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Zhonghua Yu Fang Yi Xue Za Zhi. 2009 Jul;43(7):565-70.
To determine the association between viral load of high risk human papillomavirus (HR-HPV) and cervical intraepithelial neoplasia (CIN).
Cervical exfoliated cells were collected from 18 186 women aged 17 -59 from six urban areas and eight rural areas when they were screened in the cross-sectional population-based studies from 1999 to 2008. HR-HPV was detected by the Hybrid Capture 2 (hc2) system, and viral load was measured by the ratio of relative light units to standard positive control (RLU/PC). RLU/PC was categorized for analysis into four groups: negative [0, 1.00), low viral load [1.0, 10.00), moderate viral load [10.00, 100.00), and high viral load > or = 100.00. Cervical lesions were diagnosed by biopsies as normal, CIN 1, CIN 2, CIN 3 and squamous cervical cancer (SCC). Association between HR-HPV viral load and CIN was evaluated by unconditional multinomial logistic regression.
The HR-HPV infection rate of the population was 14.51% (2515/17334). 100.00% (29/29) of SCC, 97.63% (206/211) of CIN 3, 93.43% (199/213) of CIN 2, 75.04% (421/561) of CIN 1 and 10.17% (1660/16320) of normal women were positive for HR-HPV DNA. The median RLUs for the HR-HPV positive women with SCC, CIN 3, CIN 2, CIN 1 and normal were 320.85, 158.05, 143.70, 125.34 and 9.64, respectively. There were significant differences among the distributions of viral loads in each lesion (chi2 = 6190.40, P < 0.01). The severity of CIN increased with the viral load (chi2 = 5493.35, P <0.01). Compared with the risks of CINs in HR-HPV negative population, the risks of CINs in low, moderate and high viral loads were increased gradually [OR(95% CI) : CIN 1 : 9.01(6.31 - 12.87), 24.96(18.23 - 34.17) and 68.42(51.40 - 91.08); CIN 2 : 26.44(12.07 - 57.95), 98.53(49.54 - 195.98) and 322.88(168.62 - 618.27); CIN 3+ : 72.89(24.02-221.18); 343.58(121.81-969.09) and >999.99(473.38 - >999.99)], and there were obvious dose-response relationships (chi2trend was 3115.05, 2413.95 and 3098.57, respectively. P< 0.01). In each age group of the HR-HPV positive population,the risks of CIN 2 + in the women with moderate or high viral load were higher than the one with low viral load [OR(95% CI): <35 : 4.71(1.23 - 18.09) and 15.06(4.40 - 51.49); 35 -: 4.01 (1.62 -9.90) and 14.09(6.15 -32.28); 40 - : 3.06(1.52 -6.16) and 7.78(4.05 -14.95); > or =45: 3.50(1.36 -9. 01) and 7.57(3.13 - 18. 30)], and there was a positive correlation between the risk of CIN 2+ and the viral load (chi2trend was 51.33, 66.28, 53.64 and 51.00, respectively. P <0.01). The risk of CIN 2 + was highest among the women aged 40 - with high viral load [OR (95% CI) : 2.02 (1.15 - 3.52)].
There is strong correlation between the HR-HPV viral load and the severity of CIN, and so is the correlation between the HR-HPV viral load and the risk of CIN 2 +. A moderate to high viral load of HR-HPV should be the major risk factor for the cervical cancer and CIN 2 and CIN 3, and there is a higher risk in the women aged 35 or older than the younger ones. Considering both the age and viral load could help the doctors to manage the screening women more effectively.
确定高危型人乳头瘤病毒(HR-HPV)载量与宫颈上皮内瘤变(CIN)之间的关联。
在1999年至2008年基于人群的横断面研究筛查期间,从6个城市地区和8个农村地区的18186名17-59岁女性中收集宫颈脱落细胞。采用杂交捕获2代(hc2)系统检测HR-HPV,并通过相对光单位与标准阳性对照的比值(RLU/PC)测量病毒载量。RLU/PC分为四组进行分析:阴性[0, 1.00)、低病毒载量[1.0, 10.00)、中度病毒载量[10.00, 100.00)和高病毒载量≥100.00。通过活检将宫颈病变诊断为正常、CIN 1、CIN 2、CIN 3和宫颈鳞状细胞癌(SCC)。采用非条件多项逻辑回归评估HR-HPV病毒载量与CIN之间的关联。
人群中HR-HPV感染率为14.51%(2515/17334)。SCC患者中HR-HPV DNA阳性率为100.00%(29/29),CIN 3患者为97.63%(206/211),CIN 2患者为93.43%(199/213),CIN 1患者为75.04%(421/561),正常女性为10.17%(1660/16320)。HR-HPV阳性的SCC、CIN 3、CIN 2、CIN 1和正常女性的RLU中位数分别为320.85、158.05、143.70、125.34和9.64。各病变的病毒载量分布存在显著差异(χ2 = 6190.40,P < 0.01)。CIN的严重程度随病毒载量增加而增加(χ2 = 5493.35,P <0.01)。与HR-HPV阴性人群中CIN的风险相比,低、中和高病毒载量人群中CIN的风险逐渐增加[比值比(95%可信区间):CIN 1:9.01(6.31 - 12.87),24.96(18.23 - 34.17)和68.42(51.40 - 91.08);CIN 2:26.44(12.07 - 57.95),98.53(49.54 - 195.98)和322.88(168.62 - 618.27);CIN 3+:72.89(24.02 - 221.18);343.58(121.81 - 969.09)和>999.99(473.38 - >999.99)],且存在明显的剂量反应关系(χ2趋势分别为3115.05、2413.95和3098.57。P<0.01)。在HR-HPV阳性人群的各年龄组中,中度或高病毒载量女性发生CIN 2+的风险高于低病毒载量女性[比值比(95%可信区间):<35岁:4.71(1.23 - 18.09)和15.06(4.40 - 51.49);35 - 岁:4.01(1.62 - 9.90)和14.09(6.15 - 32.28);40 - 岁:3.06(1.52 - 6.16)和7.78(4.05 - 14.95);≥45岁:3.50(1.36 - 9.01)和7.57(3.13 - 18.30)],且CIN 2+风险与病毒载量呈正相关(χ2趋势分别为51.33、66.28、53.64和51.00。P <0.01)。40 - 岁高病毒载量女性发生CIN 2+的风险最高[比值比(95%可信区间):2.02(1.15 - 3.52)]。
HR-HPV病毒载量与CIN的严重程度密切相关,与CIN 2+的风险也密切相关。HR-HPV中度至高度病毒载量应是宫颈癌及CIN 2和CIN 3的主要危险因素,35岁及以上女性的风险高于年轻女性。综合考虑年龄和病毒载量有助于医生更有效地管理筛查人群。